Today, we welcome two new additions to the Galecto leadership team: Sherwin Sattarzadeh as Chief Operating Officer and Dr Becker Hewes as Chief Medical Officer. Joining us from Blueprint Medicines, both bring deep expertise in oncology and hematology. Their leadership arrives at a perfect time as we accelerate our development of DMR-001 toward the clinic later this year. Read more: https://lnkd.in/eSJKhti3
Galecto, Inc.
Forskning inden for bioteknologi
Copenhagen, DK 5.394 følgere
Clinical stage fibrosis and cancer treatments
Om os
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.
- Websted
-
http://www.galecto.com
Eksternt link til Galecto, Inc.
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 11-50 medarbejdere
- Hovedkvarter
- Copenhagen, DK
- Type
- Privat
- Grundlagt
- 2011
- Specialer
- Galectin modulators, Galectin-3 inhibitors, Fibrosis treatment, LOXL2, Inflammation, Oncology, IPF, Liver fibrosis og Myelofibrosis
Beliggenheder
-
Se ruten
Ole Maaloes Vej 3
Cobis Science Park
Copenhagen, DK DK-2200, DK
Medarbejdere hos Galecto, Inc.
Opdateringer
-
NEWS: Galecto is proud to announce the acquisition of Damora Therapeutics, uniting powerful science and expertise to advance targeted therapies that improve outcomes for people living with blood cancers. Alongside an oversubscribed $285 million private placement, the acquisition expands Galecto’s pipeline to include Damora’s portfolio of anti-mutant calreticulin-targeted therapies. Its lead asset, DMR-001, is a potentially best-in-class monoclonal antibody against mutCALR, for which Phase 1 POC data is expected in 2027. Together, we will strive to redefine the standard‑of‑care for chronic blood disorders. Read the release: https://lnkd.in/empDe5xW #Acquisition #MutCALR #BloodCancer #Financing #Biotech
-